Nah dran
| System | Observations (Phase I/II) | |--------|---------------------------| | | No deaths; most AEs ≤ Grade 1. | | Gastro‑intestinal | Mild nausea (≈ 8 %); transient dyspepsia (≈ 5 %). | | Neurologic | No seizures, dizziness, or visual disturbances reported. | | Cardiovascular | No QTc prolongation (> 10 ms) at any dose; BP unchanged. | | Hepatic/renal | Transaminases ≤ 1.5×ULN; creatinine unchanged. | | Immunologic | Slight ↓ in peripheral IL‑6 (statistically significant at 150 mg). No opportunistic infections. | | Special populations | No data yet for elderly > 80 y, hepatic impairment, or pediatrics. |
Please provide more context or details, and I'll do my best to create a helpful and informative review.
– Phase IIa AD data show a trend toward cognitive benefit and clear biomarker movement (↓NfL). Safety remains excellent. The ongoing Phase IIb trial will be the decisive step.
Rhea tightened her grip on her weapon. “And if we don’t? What happens then?”
| System | Observations (Phase I/II) | |--------|---------------------------| | | No deaths; most AEs ≤ Grade 1. | | Gastro‑intestinal | Mild nausea (≈ 8 %); transient dyspepsia (≈ 5 %). | | Neurologic | No seizures, dizziness, or visual disturbances reported. | | Cardiovascular | No QTc prolongation (> 10 ms) at any dose; BP unchanged. | | Hepatic/renal | Transaminases ≤ 1.5×ULN; creatinine unchanged. | | Immunologic | Slight ↓ in peripheral IL‑6 (statistically significant at 150 mg). No opportunistic infections. | | Special populations | No data yet for elderly > 80 y, hepatic impairment, or pediatrics. |
Please provide more context or details, and I'll do my best to create a helpful and informative review.
– Phase IIa AD data show a trend toward cognitive benefit and clear biomarker movement (↓NfL). Safety remains excellent. The ongoing Phase IIb trial will be the decisive step.
Rhea tightened her grip on her weapon. “And if we don’t? What happens then?”
